The TULIP trial represents a pivotal phase 3 study conducted to assess the...
During ESMO 2023 MediMIx had the honour to organise a discussion on...
At ESMO 2023, exciting data on lung cancer were presented, including insights...
The AdvanTIG-202 study represents an open-label phase 2 clinical trial...
In this discussion, Prof Jean-François Beaurain, a medical oncologist at...
During ESMO 2023 Prof Hurwitz, affiliated with the Fred Hutch Cancer Center in...
Several presentations at ESMO2023 highlighted significant advancements in the...
In this insightful discussion between Dr Eline Naert, a medical oncologist from...
Medical oncologist Prof Christine Gennigens from CHU de Liège and...
In a discussion at ESMO between Dr Eline Naert, medical oncologist from Genth...